Back

Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study

2 September 2024 (09:11 - 09:30)
Organised by: Logo
Congress Presentation Part of: Repurposing anti-diabetic pharmacotherapy: the new cure for all evils? Antidiabetic Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Gwo-Ping Jong

Chung Shan Medical University Hospital, Taichung (Taiwan)

3 More presentations in this session

Presentation thumbnail
State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?
Associate Professor A. Navar (Dallas, US)
Slides Video
Presentation thumbnail
Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK
Ms H. Yang (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
Doctor D. Garcia Vega (Ourense, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 09:11 CET
You may be interested in
thumbnail
Congress Session
Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?
thumbnail
Congress Presentation
Effects of SGLT2 inhibitors on the cardiovascular outcomes in patients with cancer: a systematic review and meta-analysis
thumbnail
Congress Presentation
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources